한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제25권3호
  • /
  • Pages.200-208
  • /
  • 2015
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지

급성관상동맥 증후군 치료를 위한 국내·외 항혈소판제 약물요법 가이드라인 비교 연구

A Comparative Study the USA, Europe and Korea Guidelines of Antiplatelet Therapy for Patients with Acute Coronary Syndrome

  • 투고 : 2015.05.20
  • 심사 : 2015.08.12
  • 발행 : 2015.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: Patients with acute coronary syndrome (ACS) are typically managed with dual antiplatelet therapy of acetylsalicylic acid (aspirin) and $P2Y_{12}$ receptor inhibitor. In this study, we discussed current and previous antiplatelet therapy guidelines and compared with guidelines of the USA (ACC/AHA), Europe (ESC) and Korea (KSC). Method: This study investigated from ACC/AHA Joint Guidelines (the USA), ESC Clinical Practice Guidelines (Europe) and Korea Society of Interventional Cardiology (Korea) web site, respectively. Results: It is significant that difference between the current and the previous guidelines was integration of terminology from clopidogrel to $P2Y_{12}$ receptor inhibitors since prasugrel and ticagrelor, new antiplatelet drugs, has been added. The other difference was all three guidelines has differences in dose of aspirin. The most notable difference was class of recommendation(COR) in $P2Y_{12}$ receptor inhibitors. ACC/AHA and Korean guidelines recommend clopidogrel, prasugrel, and ticagrelor with COR IB; whereas, ESC recommend prasugrel and ticagrelor with IB which is higher than clopidogrel with IC. Conclusion: This research addresses important movement to revise the Korean existing guideline recommendations. New Korean antiplatelet therapy guideline should be avoiding obvious differences in ACC/AHA and ESC guidelines and harmonizing international guidelines.

키워드

참고문헌

  1. Overbaugh, Kristen J. Acute coronary syndrome. AJN 2009;109(5):42-52.
  2. Yun DD, Alpert JS. Acute coronary syndromes. Cardiology 1997;88:223-37. https://doi.org/10.1159/000177335
  3. Park SJ. Acute coronary syndrome. Korean Circulation J 1998;28(12):2066-75. https://doi.org/10.4070/kcj.1998.28.12.2066
  4. Molife C, Frech-Tamas F, DeKoven M, et al. Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor. J Med Econ, in press.
  5. Fanari Z, Weiss S, Weintraub WS. Cost effectiveness of antiplatelet and antithrombotic therapy in the setting of acute coronary syndrome: current perspective and literature review. Am J Cardiovasc Drugs, in press.
  6. Kim J, Lee E, Lee T, Sohn A. Economic burden of acute coronary syndrome in South Korea: a national survey. BMC Cardiovasc Disord 2013;13(55):1-8. https://doi.org/10.1186/1471-2261-13-1
  7. Korsnes JS, Davis KL, Ariely R, et al. Health care resource utilization and costs associated with nonfatal major adverse cardiovascular events. J Manag Care Spec Pharm 2015;21(6):443-50. https://doi.org/10.18553/jmcp.2015.21.6.443
  8. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction a report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction). Circulation. 2007;116:e148-e304. https://doi.org/10.1161/CIRCULATIONAHA.107.181940
  9. Vos GJ, Bennaghmouch N, Qaderdan K, et al. Management of the patient with an acute coronary syndrome using oral anticoagulation. Neth Heart J, in press.
  10. Brener SJ, Maehara A, Mintz GS, et al. Effect of prior aspirin treatment on patients with acute coronary syndromes: insights from the PROSPECT study. J Invasive Cardiol, in press.
  11. Johnson SG, Gruntowicz D, Chua T, et al. Financial analysis of CYP2C19 genotyping in patients receiving dual antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention. J Manag Care Spec Pharm 2015;21(7):552-7. https://doi.org/10.18553/jmcp.2015.21.7.552
  12. Wei YQ, Wang DG, Yang H, et al. Cytochrome P450 CYP 2C19*2 Associated with adverse 1-year cardiovascular events in patients with acute coronary syndrome. PLoS One 2015;10(7):1-8.
  13. Kim IS, Choi BR, Jeong YH, et al. The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome. J Thromb Haemost 2009;7(5):897-9. https://doi.org/10.1111/j.1538-7836.2009.03319.x
  14. Rollini F, Angiolillo DJ, Cattaneo M. The GRAVITAS study. G Ital Cardiol 2012;13(1):1-5.
  15. Bavishi C, Panwar S, Messerli FH, et al. Meta-analysis of comparison of the newer oral $P2Y_{12}$ inhibitors (prasugrel or ticagrelor) to clopidogrel in patients with non-ST-Elevation acute coronary syndrome. Am J Cardiol, in press.
  16. De Servi S, Goedicke J, Schirmer A, et al. Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. Eur Heart J Acute Cardiovasc Care 2014;3(4):363-72. https://doi.org/10.1177/2048872614534078
  17. Patel MR, Becker RC, Wojdyla DM, et al. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. Eur J Prev Cardiol 2015;22(6):734-42. https://doi.org/10.1177/2047487314533215
  18. Kang HJ, Clare RM, Gao R, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the platelet inhibition and patient outcomes (PLATO) trial. Am Heart J 2015;169(6):899-905. https://doi.org/10.1016/j.ahj.2015.03.015
  19. Paramo JA. New era in antiplatelet therapy based on results from recent clinical trials. Med Clin 2011;137(11):504-8. https://doi.org/10.1016/j.medcli.2010.09.015
  20. Gandhi S, Zile B, Tan MK, et al. Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective. Can J Cardiol 2014;30(12):1725-31. https://doi.org/10.1016/j.cjca.2014.09.011
  21. Huber K, Lip GY. Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes. Thromb Haemost 2013;110(1):11-3. https://doi.org/10.1160/TH13-06-0453
  22. AmericanHeartAssociation (http://my.americanheart.org/professional/StatementsGuidelines/ByTopic/TopicsA-C/ACCAHA-Joint-Guidelines_UCM_321694_Article.jsp)
  23. European Society of Cardiology (http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/ESC-Clinical-Practice-Guidelines-list/listing)
  24. Woo JS, Kim MK. Updates in the management of patients with acute coronary syndrome. Korean J Med 2009;76(6):661-676.
  25. Korea Society of Interventional Cardiology (http://www.kscvi.org/new_ksic2015/ksic_data/board/lists/page/1/b_id/5)
  26. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol 2013;61(4):e78-140. https://doi.org/10.1016/j.jacc.2012.11.019
  27. Kushner FG, Hand M, Smith SC Jr, et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update). J Am Coll Cardiol 2009;54(23):2205-2241. https://doi.org/10.1016/j.jacc.2009.10.015
  28. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol 2012;60(7):645-681. https://doi.org/10.1016/j.jacc.2012.06.004
  29. Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2011;123(18):e426-e579. https://doi.org/10.1161/CIR.0b013e318212bb8b
  30. Steg G, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33(20):2569-2619. https://doi.org/10.1093/eurheartj/ehs215
  31. Hamm W, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J 2011;32(23):2999-3054. https://doi.org/10.1093/eurheartj/ehr236
  32. Krumholz HM, Anderson JL, Brooks NH, et al. ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American college of cardiology/American heart association task force on performance measures (writing committee to develop performance measures on ST-elevation and non-ST-elevation myocardial infarction). Circulation 2006;113(5):732-761. https://doi.org/10.1161/CIRCULATIONAHA.106.172860
  33. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008 performance measures for sdults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American college of cardiology/American heart association task force on performance measures (writing committee to develop performance measures for ST-elevation and non-ST-elevation myocardial infarction). Circulation 2008;118(24):2598-2648.
  34. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2014;62(24):e139-228.
  35. Kander T, Dankiewicz J, Friberg H, et al. Platelet aggregation and clot formation in comatose survivors of cardiac arrest treated with induced hypothermia and dual platelet inhibition with aspirin and ticagrelor; a prospective observational study. Crit Care 2014;18(5):495. https://doi.org/10.1186/s13054-014-0495-z
  36. Kander T, Brokopp J, Erlinge D, et al. Temperature effects on haemostasis in whole blood from ticagrelor- and aspirin-treated patients with acute coronary syndrome. Scand J Clin Lab Invest 2015;75(1):27-35. https://doi.org/10.3109/00365513.2014.965735
  37. Berger JS. Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes. Am J Cardiol 2013;112(5):737-745. https://doi.org/10.1016/j.amjcard.2013.04.055
  38. Xian Y, Wang TY, McCoy LA, et al. Association of discharge aspirin dose with outcomes after acute myocardial infarction: insights from the treatment with ADP receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) Study. Circulation 2015;132(3):174-181. https://doi.org/10.1161/CIRCULATIONAHA.114.014992
  39. Serebruany VL, Pershukov IV. The differences between the guidelines of the European society of cardiology and the American college of cardiology/American heart association for oral $P2Y_{12}$ inhibitor therapy in the management of patients with acute coronary syndromes. Kardiologiia 2013;53(7):70-77.
  40. Wouter JJ, Collet JP, De Luca L. Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. Curr Med Res Opin 2012;28(2):203-211. https://doi.org/10.1185/03007995.2011.651526
  41. Rahman A, Latona J. New oral anticoagulants and perioperative management of anticoagulant/antiplatelet agents. Aust Fam Physician 2014;43(12):861-866.
  42. Htun WW, Steinhubl SR. Ticagrelor: the first novel reversible P2Y(12) inhibitor. Expert Opin Pharmacother 2013;14(2):237-245. https://doi.org/10.1517/14656566.2013.757303
  43. Serebruany VL, DiNicolantonio JJ. Viewpoint: mismatch between the European and American guidelines on oral antiplatelet $P2Y_{12}$ inhibitors after acute coronary syndromes. Thromb Haemost 2013;110(1):5-10. https://doi.org/10.1160/TH13-02-0142
  44. Linn CE, Shah NK, Epstein BJ. Role of CYP450 in antiplatelet therapy: considerations for patients at risk for further cardiovascular or cerebrovascular problems. J Pharm Technol 2013;29(2):72-77. https://doi.org/10.1177/875512251302900205
  45. Caldeira D, Pinto F, Ferreira J. Dyspnea and reversibility profile of P2Y antagonists: systematic review of new antiplatelet drugs. Am J Cardiovasc Drugs 2014;14(4):303-311. https://doi.org/10.1007/s40256-014-0071-6
  46. Kazi, DS, Garber AM, Shah RU, et al. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Inter Med 2014;160(4):221-232. https://doi.org/10.7326/M13-1999
  47. Yamwong S, Permsuwan U, Tinmanee S, et al. Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand. Health Econ Rev 2014;4(1):17. https://doi.org/10.1186/s13561-014-0017-3
  48. Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004;110(10):1226-30. https://doi.org/10.1161/01.CIR.0000140721.27004.4B
  49. Bahler CK, Hann CR, Fjield T, et al. Second-generation trabecular meshwork bypass stent (iStent inject) increases outflow facility in cultured human anterior segments. Am J Ophthalmol 2012;153(6):1206-13. https://doi.org/10.1016/j.ajo.2011.12.017
  50. Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 2014;64(20):2086-97. https://doi.org/10.1016/j.jacc.2014.09.008
  51. Alexopoulos D, Xanthopoulou I, Plakomyti TE, et al. Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis. Am J Kidney Dis 2012;60(2):332-3. https://doi.org/10.1053/j.ajkd.2012.05.001
  52. Norgard, NB, Dinicolantonio JJ. Clopidogrel, prasugrel, or ticagrelor? A practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Postgrad Med 2013;125(4):91-102.
  53. Ticagrelor (Brilinta) - better than clopidogrel (Plavix)? Med Lett Drugs Ther 2011;53(1372):69-70.
  54. Rafeedheen R, Bliden KP, Liu F, et al. Novel antiplatelet agents in cardiovascular medicine. Curr Treat Options Cardiovasc Med. 2015 Jun;17(6):383.
  55. Guideline for pharmacotherapy of anti-platelet agent for acute coronary syndrome. Korea Society of Interventional Cardiology (2012)
  56. Sorich MJ, Rowland A, McKinnon RA, et al. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet 2014;7(6):895-902.
  57. Oh IY, Park KW, Kang SH, et al. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart 2012;98(2):139-44. https://doi.org/10.1136/hrt.2011.227272